Alnylam slides as valuation worries linger after Jefferies downgrade reset
Alnylam Pharmaceuticals shares fell 3.58% to $309.15 as investors continued to reprice the stock after a recent analyst reset that highlighted valuation risk. The slide follows Jefferies’ March 16, 2026 downgrade to Hold with a sharply lower price target, keeping pressure on sentiment into mid-April trading. (benzinga.com)
1) What’s moving ALNY today
Alnylam Pharmaceuticals (ALNY) traded lower Friday, April 17, 2026, extending a pullback that has been tied to valuation concerns after a recent analyst reset. The stock’s down move fits a pattern seen in recent sessions where the market has focused less on long-dated pipeline upside and more on near-term revenue durability, net pricing, and how much optimism is already embedded in the multiple. (quiverquant.com)
2) The key catalyst investors keep pointing to
A major overhang has been Jefferies’ downgrade of Alnylam to Hold on March 16, 2026, paired with a materially reduced price target. Even though the call is not new today, it has served as an anchor for the market’s reassessment of how to value Alnylam’s growth profile, particularly as the company moves deeper into commercialization and investors debate how much of the TTR-franchise trajectory is already priced in. (benzinga.com)
3) What to watch next
Traders are watching for fresh company-specific updates that could break the valuation narrative, including any new detail on 2026 expectations and upcoming milestones highlighted in recent materials. Until a new catalyst lands, ALNY may continue to trade with higher sensitivity to incremental changes in analyst positioning and broader risk appetite in biotech. (quiverquant.com)